Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer

Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer

Summary: CDK4/6 inhibitors are effective against cancer cells expressing the tumor suppressor RB1, but not RB1-deficient cells, posing the challenge of how to target RB1 loss. In triple-negative breast cancer (TNBC), RB1 and PTEN are frequently inactivated together with TP53. We performed kinome/pho...

Full description

Bibliographic Details
Main Authors: Jeff C. Liu, Letizia Granieri, Mariusz Shrestha, Dong-Yu Wang, Ioulia Vorobieva, Elizabeth A. Rubie, Rob Jones, YoungJun Ju, Giovanna Pellecchia, Zhe Jiang, Carlo A. Palmerini, Yaacov Ben-David, Sean E. Egan, James R. Woodgett, Gary D. Bader, Alessandro Datti, Eldad Zacksenhaus
Format: Article
Language:English
Published: Elsevier 2018-04-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124718303814

Internet

http://www.sciencedirect.com/science/article/pii/S2211124718303814

Similar Items